Skip to main content

CORRECTION article

Front. Pharmacol., 03 November 2022
Sec. Ethnopharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1074679

Corrigendum: A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial

This article is a correction to:

  1. A chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial

    1. Read original article
Yingying Wan&#x;Yingying Wan1†Jiaxi Yang&#x;Jiaxi Yang2†Tianyue MaTianyue Ma2Wenqian WangWenqian Wang2Haonan WangHaonan Wang1Wenting SunWenting Sun1Wanting YeWanting Ye2Lin YangLin Yang1Qiuai Kou Qiuai Kou1*
  • 1Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
  • 2Beijing University of Chinese Medicine, Beijing, China

A Corrigendum on:
A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial

by Wan Y, Yang J, Ma T, Wang W, Wang H, Sun W, Ye W, Yang L and Kou Q (2022). Front Pharmacol. 13: 945565. doi: 10.3389/fphar.2022.945565

In the published article, Jianxun Ren was erroneously included. The corrected author list and correspondence information appear below. Additionally, the Author contributions section has been revised to reflect this amendment.

Yingying Wan1†, Jiaxi Yang2†, Tianyue Ma2, Wenqian Wang2, Haonan Wang1, Wenting Sun1, Wanting Ye2, Lin Yang1 and Qiuai Kou1*

Correspondence: Qiuai Kou, kouqiuai@163.com

Author Contributions: QK, YW, and JY contributed to the study design. YW drafted the manuscript, and prepared the additional files. JY was responsible for obtaining ethics approval. TM, WW, HW, WY, and WS devised and discussed the study design. LY analyzed the main components of the Chinese medicine. All authors have read and agreed with the final manuscript.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: rheumatoid arthritis, female, randomized controlled trial, double-blind, placebo, Chinese medicine, protocol

Citation: Wan Y, Yang J, Ma T, Wang W, Wang H, Sun W, Ye W, Yang L and Kou Q (2022) Corrigendum: A Chinese medicine formula (kunbixiao granule) for female rheumatoid arthritis: Study protocol for a double-blind, randomized, placebo-controlled trial. Front. Pharmacol. 13:1074679. doi: 10.3389/fphar.2022.1074679

Received: 19 October 2022; Accepted: 20 October 2022;
Published: 03 November 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Wan, Yang, Ma, Wang, Wang, Sun, Ye, Yang and Kou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qiuai Kou, kouqiuai@163.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.